NeoImmuneTech

Privately held: no public share price · United States

Assets

(1 total)
1Total Assets
1Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Approved
Amino AcidSmall molecule
Sickle Cell Disease

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

26 June 2025ApprovalL-glutamine (Endari)FDA approves Endari label changes
US, FDA · Source ↗

Financial reports

No financial reports recorded.